Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer

Abstract

The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-of-function mutations in either BRCA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs. It has been demonstrated previously that inhibiting elements of the cellular DNA maintenance pathways represents a novel therapeutic approach to treating tumors in these individuals. Here, we show that inhibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA deficiency. We also demonstrate that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the centrosome amplification phenotype associated with BRCA deficiency. We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-associated cancers.

DOI: 10.1038/onc.2008.483
05020102011201220132014201520162017
Citations per Year

189 Citations

Semantic Scholar estimates that this publication has 189 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{McCabe2009TargetingT1, title={Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer}, author={Nuala McCabe and Maria Antonietta Cerone and Tomokazu Ohishi and Hiroyuki Seimiya and Christopher J Lord and Ann Ashworth}, journal={Oncogene}, year={2009}, volume={28}, pages={1465-1470} }